RxDoctor Payments Data

Liliana Garcia-Vargas, MD

Endocrinology, Diabetes & Metabolism · Yorktown, INNPI 1972709079

Payments from drug & device makers

$328in general payments, 2019–2025

Across 4 payments — averaging $81.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$132
  • Mannkind Corporation$123
  • Intuitive Surgical$41
  • Novo Nordisk$32

What the payments were for

  • Food & beverage$29590%
  • Education$3210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$328 in reported general payments places this provider in the 25th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.

See all endocrinology, diabetes & metabolism providers in Indiana

Medicare billing

Part B allowed, 2024
$477,857
Medicare patients
446
Services billed
25,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ForteoTeriparatide131$529,212
OzempicSemaglutide246$387,302
JardianceEmpagliflozin168$197,782
TymlosAbaloparatide38$94,120
TrulicityDulaglutide47$86,568
Teriparatide37$77,872
MounjaroTirzepatide56$64,108
Tresiba Flextouch U-200Insulin Degludec48$52,851
RybelsusSemaglutide35$46,592
AfrezzaInsulin Regular, Human15$38,308
JanuviaSitagliptin Phosphate33$25,939
FarxigaDapagliflozin Propanediol25$25,889
Tresiba Flextouch U-100Insulin Degludec46$22,809
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$21,856
Humalog Kwikpen U-100Insulin Lispro72$21,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$32$433,893281 claims
Mannkind CorporationAfrezza$123$38,30815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.

Other endocrinology, diabetes & metabolism in Yorktown

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →